Adaptive Biotechnologies and Flatiron Health Announce Integration of Clonoseq®? Mrd Testing into Oncoemr®?

Published: 2025-07-01 15:06:02 ET ADPT

Published on 07/01/2025 at 15:06

Adaptive Biotechnologies Corporation and Flatiron Health announced the integration of Adaptive's clonoSEQ test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR®?, Flatiron's cloud-based Electronic Medical Record (EMR) platform. Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status. MRD refers to the small number of cancer cells that may remain in a patient's body during and after treatment and may eventually lead to disease recurrence.

MRD status is one of the strongest predictors of outcomes in blood cancer patients and routine testing provides a personalized way to track a patient's individual response to treatment and inform clinical decision-making to optimize care. This integration will be effective as of July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.